论文部分内容阅读
碳酸酐酶抑制剂自1954年开始用于眼科,但其副作用发生率高,估计仅约半数的青光眼患者能够耐受长期全身使用足量的碳酸酐酶抑制剂进行治疗,因而限制了这种药物的应用。为了减少全身性副作用,一些学者主张局部应用碳酸酐酶抑制剂。但是,50年代的研究表明,醋唑磺胺局部滴眼、结膜下注射、玻璃体内注射、前房内注射或电离子透入疗法等,在动物试验中均不能降低眼压。其它碳酸酐酶抑制剂如甲醋唑胺、乙氧苯噻唑磺胺和二氯磺胺等,局部应用都无效。因此,许多学者认为,局部应用碳酸酐酶抑制剂是不可能的。
Carbonic anhydrase inhibitors have been used in ophthalmology since 1954 but have a high incidence of side effects and it is estimated that only about half of patients with glaucoma are refractory to long-term systemic use of sufficient carbonic anhydrase inhibitors for treatment, thus limiting the drug Applications. In order to reduce systemic side effects, some scholars advocate topical application of carbonic anhydrase inhibitors. However, studies in the 1950s showed that topical eye drops of acetosulfuron, subconjunctival injections, intravitreal injections, anterior chamber injections or iontophoresis did not reduce intraocular pressure in animal studies. Other carbonic anhydrase inhibitors such as methazolamide, phenoxythiazole sulfonamide and dichloro sulfonamide and other topical applications are ineffective. Therefore, many scholars believe that topical carbonic anhydrase inhibitors are not possible.